drugset / Trial / NCT06069830
PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
A prospective, open-abel, phase 2 clinical study to investigate whether interim Positron Emission Tomography (PET) and Epstein-Barr virus (EBV) DNA-directed therapy can improve the prognosis of localized nasal extranodal NK/T cell lymphoma (ENKTL) patients.
Timeline
- Start
- 2023-12-06
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Etoposide | Small molecule | 200 mg | Oral |
| Subject | Pegaspargase | Protein / enzyme biologic | 2500 unknown | Intramuscular |